Sarepta Therapeutics (SRPT) Net Equity Issued and Repurchased (2010 - 2020)

Sarepta Therapeutics' Net Equity Issued and Repurchased history runs 11 years deep, the most recent figure standing at -$4.3 million for Q2 2020.

• On a quarterly basis, Net Equity Issued and Repurchased fell 4914.61% year-over-year to -$4.3 million in Q2 2020; TTM through Dec 2024 was -$4.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $20.0 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased eased to -$4.3 million in Q2 2020 per SRPT's latest filing, from $316.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $470.4 million in Q4 2018 and bottomed at -$4.3 million in Q2 2020.
• The 5-year median for Net Equity Issued and Repurchased is $10.6 million (2018), against an average of $119.4 million.
• Across the five-year window, Net Equity Issued and Repurchased surged 7634.47% in 2016 and plunged 4914.61% in 2020, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$149000.0 in 2016, then jumped by 234914.09% to $349.9 million in 2017, then surged by 34.44% to $470.4 million in 2018, then tumbled by 100.0% to $1000.0 in 2019, then sank by 428600.0% to -$4.3 million in 2020.
• Per Business Quant, the three latest SRPT Net Equity Issued and Repurchased figures stand at -$4.3 million (Q2 2020), $316.3 million (Q1 2020), and $1000.0 (Q4 2019).